The Changing Aetiology of Head and Neck Cancer: The Role of Human Papillomavirus

Clinical Oncology

Volumn 22, Issue 7, 2010, Pages 538-546

  Evans, M ^a   Powell, N G ^b  

^a VELINDRE CANCER CENTRE   (United Kingdom)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Head and neck; Human papillomavirus; Oropharyngeal

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SCREENING; CARCINOGENESIS; CLINICAL FEATURE; CLINICAL PROTOCOL; HEAD AND NECK CANCER; HUMAN; INFECTION PREVENTION; MULTIPLE CYCLE TREATMENT; OROPHARYNX CANCER; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL TIME; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA; VIRUS DETECTION; WART VIRUS;

EID: 77955661337     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.05.024     Document Type: Article

References (64)

1. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
2. De Vuyst H., Clifford G.M., Nascimento M.C., Madeleine M.M., Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009, 124:1626-1636.
3. Miralles-Guri C., Bruni L., Cubilla A.L., Castellsague X., Bosch F.X., de Sanjose S. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 2009, 62:870-878.
4. Anon Cancer Statistics: registrations series MB1 Available from:, Accessed 2 April 2010. http://www.statistics.gov.uk/statbase/Product.asp%3Fvlnk%3D8843.
5. D'Souza G., Kreimer A.R., Viscidi R., et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007, 356:1944-1956.
6. Kreimer A.R., Clifford G.M., Boyle P., Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005, 14:467-475.
7. Nasman A., Attner P., Hammarstedt L., et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma?. Int J Cancer 2009, 125:362-366.
8. Romanitan M., Nasman A., Ramqvist T., et al. Human papillomavirus frequency in oral and oropharyngeal cancer in Greece. Anticancer Res 2008, 28:2077-2080.
9. Herrero R., Castellsague X., Pawlita M., et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003, 95:1772-1783.
10. Begum S., Cao D., Gillison M., Zahurak M., Westra W.H. Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res 2005, 11:5694-5699.
11. Anderson C.E., McLaren K.M., Rae F., Sanderson R.J., Cuschieri K.S. Human papilloma virus in squamous carcinoma of the head and neck: a study of cases in south east Scotland. J Clin Pathol 2007, 60:439-441.
12. Munoz N., Bosch F.X., de Sanjose S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
13. Smith J.S., Lindsay L., Hoots B., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121:621-632.
14. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63:1129-1136.
15. Veldman T., Horikawa I., Barrett J.C., Schlegel R. Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J Virol 2001, 75:4467-4472.
16. Veldman T., Liu X., Yuan H., Schlegel R. Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc Natl Acad Sci USA 2003, 100:8211-8216.
17. Munger K., Baldwin A., Edwards K.M., et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004, 78:11451-11460.
18. Middleton K., Peh W., Southern S., et al. Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J Virol 2003, 77:10186-10201.
19. Chung C.H., Gillison M.L. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res 2009, 15:6758-6762.
20. Pett M., Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis?. J Pathol 2007, 212:356-367.
21. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006, 110:525-541.
22. Perry M.E. The specialised structure of crypt epithelium in the human palatine tonsil and its functional significance. J Anat 1994, 185(Pt 1):111-127.
23. Herrero R., Castle P.E., Schiffman M., et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005, 191:1796-1807.
24. Hibbitts S., Jones J., Powell N., et al. Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: a cross-sectional study. Br J Cancer 2008, 99:1929-1933.
25. Wheeler C.M., Hunt W.C., Joste N.E., Key C.R., Quint W.G., Castle P.E. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009, 101:475-487.
26. Adelstein D.J., Ridge J.A., Gillison M.L., et al. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck 2009, 31:1393-1422.
27. Kreimer A.R., Alberg A.J., Daniel R., et al. Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis 2004, 189:686-698.
28. Hemminki K., Dong C., Frisch M. Tonsillar and other upper aerodigestive tract cancers among cervical cancer patients and their husbands. Eur J Cancer Prev 2000, 9:433-437.
29. Mork J., Lie A.K., Glattre E., et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001, 344:1125-1131.
30. Hansson B.G., Rosenquist K., Antonsson A., et al. Strong association between infection with human papillomavirus and oral and oropharyngeal squamous cell carcinoma: a population-based case-control study in southern Sweden. Acta Otolaryngol 2005, 125:1337-1344.
31. Applebaum K.M., Furniss C.S., Zeka A., et al. Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. J Natl Cancer Inst 2007, 99:1801-1810.
32. Samama B., Plas-Roser S., Schaeffer C., Chateau D., Fabre M., Boehm N. HPV DNA detection by in situ hybridization with catalyzed signal amplification on thin-layer cervical smears. J Histochem Cytochem 2002, 50:1417-1420.
33. Jung A.C., Briolat J., Millon R., et al. Biological and clinical relevance of transcriptionally active human papillomavirus (HPV) infection in oropharynx squamous cell carcinoma. Int J Cancer 2010, 126:1882-1894.
34. Weinberger P.M., Yu Z., Haffty B.G., et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006, 24:736-747.
35. Klaes R., Friedrich T., Spitkovsky D., et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001, 92:276-284.
36. Gillison M., Harris J., Westra C., et al. Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129. J Clin Oncol 2009, 27:15s.
37. Fakhry C., Gillison M.L. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 2006, 24:2606-2611.
38. Goldenberg D., Begum S., Westra W.H., et al. Cystic lymph node metastasis in patients with head and neck cancer: an HPV-associated phenomenon. Head Neck 2008, 30:898-903.
39. Gillison M.L., Koch W.M., Capone R.B., et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000, 92:709-720.
40. Mellin H., Friesland S., Lewensohn R., Dalianis T., Munck-Wikland E. Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer 2000, 89:300-304.
41. Ritta M., De Andrea M., Mondini M., et al. Cell cycle and viral and immunologic profiles of head and neck squamous cell carcinoma as predictable variables of tumor progression. Head Neck 2009, 31:318-327.
42. Fakhry C., Westra W.H., Li S., et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008, 100:261-269.
43. Jo S., Juhasz A., Zhang K., et al. Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial. Anticancer Res 2009, 29:1467-1474.
44. Kies M.S., Holsinger F.C., Lee J.J., et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010, 28:8-14.
45. Worden F.P., Hooton J., Lee A., et al. Association of tobacco (T) use with risk of distant metastases (DM), tumor recurrence, and death in patients (pts) with HPV-positive (+) squamous cell cancer of the oropharynx (SCCOP). J Clin Oncol 2009, 27:15s.
46. Kumar B., Cordell K.G., Lee J.S., et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008, 26:3128-3137.
47. Worden F.P., Kumar B., Lee J.S., et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 2008, 26:3138-3146.
48. Lassen P., Eriksen J.G., Hamilton-Dutoit S., Tramm T., Alsner J., Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009, 27:1992-1998.
49. Lindel K., Beer K.T., Laissue J., Greiner R.H., Aebersold D.M. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 2001, 92:805-813.
50. Mellin Dahlstrand H., Lindquist D., Bjornestal L., et al. P16(INK4a) correlates to human papillomavirus presence, response to radiotherapy and clinical outcome in tonsillar carcinoma. Anticancer Res 2005, 25:4375-4383.
51. Licitra L., Perrone F., Bossi P., et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006, 24:5630-5636.
52. Albers A., Abe K., Hunt J., et al. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res 2005, 65:11146-11155.
53. Hoffmann T.K., Arsov C., Schirlau K., et al. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer 2006, 118:1984-1991.
54. Naucler P., Ryd W., Tornberg S., et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009, 101:88-99.
55. Snijders P.J., Steenbergen R.D., Heideman D.A., Meijer C.J. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006, 208:152-164.
56. Bhide S.A., Miah A.B., Harrington K.J., Newbold K.L., Nutting C.M. Radiation-induced xerostomia: pathophysiology, prevention and treatment. Clin Oncol (R Coll Radiol) 2009, 21:737-744.
57. Machtay M., Moughan J., Trotti A., et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008, 26:3582-3589.
58. Rathmell A.J., Ash D.V., Howes M., Nicholls J. Assessing quality of life in patients treated for advanced head and neck cancer. Clin Oncol (R Coll Radiol) 1991, 3:10-16.
59. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
60. Laino C. HPV-positive oropharyngeal tumours associated with better outcomes. Oncol Times 2009, 31:26-29.
61. Zhou J., Sun X.Y., Stenzel D.J., Frazer I.H. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991, 185:251-257.
62. Harper D.M., Franco E.L., Wheeler C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367:1247-1255.
63. Paavonen J., Jenkins D., Bosch F.X., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369:2161-2170.
64. Future II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356:1915-1927.